公开(公告)号：EP3443962A1

公开(公告)日：2019-02-20

申请号：EP17781938.0

申请日：2017-04-14

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： CHEN, Jie ,  HAN, Xi ,  JIANG, Hai ,  WANG, Xunqiang

IPC分类号： A61K31/4709 ,  A61P35/00

摘要： Provided in the present invention is a quinoline derivative for treating gastric cancer. 1-[[[4-(4-fluoro-2-methyl-1 H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt, a hydrate or a prodrug thereof as provided in the present application can effectively treat gastric cancer, and can stabilize or relieve the state of illness of a gastric cancer patient.

公开(公告)号：EP4174087A1

公开(公告)日：2023-05-03

申请号：EP21833511.5

申请日：2021-06-30

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： SU, Nan ,  ZHANG, Xiquan ,  CHEN, Jie ,  WANG, Xunqiang ,  LI, Kun ,  YU, Ding ,  WANG, Rongliang

IPC分类号： C07K16/28 ,  C12N15/13 ,  A61K39/395 ,  A61P37/02

摘要： The present invention belongs to the field of biomedicines, relates to a drug for treating tumors, and provides use of an anti-PD-L1 antibody or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer. Also provided is use of the anti-PD-L1 antibody or the pharmaceutical composition thereof in preparation of a drug for treating a MSI-H and/or dMMR tumor. In addition, also provided is use of a pharmaceutical combination of the anti-PD-L1 antibody and Anlotinib or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer.